Paul Wolski
About Paul Wolski
Paul Wolski is a Postdoctoral Fellow at Sandia National Laboratories and the Founder of Berkeley Pharmaceuticals, with a background in protein engineering and antibody engineering.
Current Positions
Paul Wolski holds several key current positions. He is a Postdoctoral Fellow at Sandia National Laboratories in Emeryville, CA, a role he has held since 2018. Additionally, he is the Founder of Berkeley Pharmaceuticals in the San Francisco Bay Area. Furthermore, Wolski is a Research Affiliate at UC Berkeley, also a position he has held since 2014.
Previous Professional Experience
Paul Wolski has a robust history of academic and professional roles. He was an Adjunct Professor at San Francisco State University, Holy Names University, and the University of San Francisco between 2017 and 2018. He also served as an Instructor at Stanford University in 2017 and 2016. Additionally, he worked as a Teacher at El Cerrito High School and a Lecturer in Analytical Chemistry at UC Berkeley in 2016. He also held the role of Chief Scientific Officer at Algas Biotech from 2015 to 2018.
Educational Background
Paul Wolski's educational credentials are impressive. He earned a Doctor of Philosophy (PhD) in Comparative Biochemistry from UC Berkeley between 2009 and 2013. Prior to that, he obtained a Bachelor of Science (BS) in Biological Sciences with a concentration in Molecular and Cell Biology from Cornell University from 2004 to 2008. Additionally, he studied Management of Technology, earning a Certificate from UC Berkeley’s College of Engineering from 2010 to 2012.
Research and Technical Expertise
Paul Wolski has significant experience in advanced research and technical fields. He applied protein engineering techniques to enhance cellulase stability in ionic liquids for biofuel applications and conducted stabilization of enzymes using differential scanning calorimetry. He has a strong background in antibody engineering, including checkpoint inhibitors, and has experience in crystallography for understanding structure-function relationships in novel protein generation.
Entrepreneurial Ventures and Competitions
Paul Wolski has participated in the final round of Y Combinator's investment process twice, seeking investment for novel immunotherapy ideas. He has experience analyzing and working with new companies through his involvement in the Venture Capital Investment Competition at Haas School of Business, UC Berkeley. As Vice President at the Energy Biosciences Institute at UC Berkeley, he had further impact on entrepreneurial and biosciences initiatives.